FDA approves J&J prostate cancer treatment

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson’s Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy. The drug is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, the regulator said. (bit.ly/2F072ih) The approval comes when Johnson & Johnson’s b...